CONNECT WITH US
HealthTech

HealthTech

Morphea linked to higher risk for cancer

Medical Xpress logo

Published on

Add as a preferred source on Google
Morphea linked to higher risk for cancer

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Morphea is associated with excess cancer incidence, according to a study published online Nov. 11 in JAMA Dermatology.

Jessica Muha, from McGill University in Montreal, and colleagues examined whether patients with morphea have an increased risk of cancer compared to the general population and patients with systemic sclerosis (SSc). The analysis included 6,181 patients with morphea and 8,133 patients with SSc identified from Canadian administrative health databases (1996 to 2019 with follow-up through 2020).

The researchers found that during the study period, 12.65% of patients with morphea and 13.57% with SSc developed cancer, yielding an increased overall cancer incidence (morphea: standardized incidence ratio [SIR], 1.24; SSc: SIR, 1.37). In both cohorts, solid tumor risk was elevated (morphea SIR, 1.17; SSc SIR, 1.21). Hematologic cancer risk was only significantly elevated in patients with SSc (SIR, 2.40; 95% confidence interval [CI], 1.92 to 2.96) but not those with morphea (SIR, 1.34; 95% CI, 0.97 to 1.81).

In the morphea group, female reproductive and breast cancers predominated, while lung cancer was most frequent among patients with SSc. The highest relative risk was seen in younger patients. Immunosuppressant use was associated with lower cancer risk in both cohorts (morphea: hazard ratio [HR], 0.56; SSc: HR, 0.63).

"These findings suggest that morphea, like SSc, is associated with excess cancer incidence and merits oncologic attention, despite historically receiving little investigation," the authors write.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.